Trial reportLeukemia2022
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07476729 (International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group), which is not on this map. Cited by 55 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
13.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07476729 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- Targeted therapies in pediatric B-Cell acute lymphoblastic leukemia: mechanisms, efficacy, and future directions.Frontiers in pharmacology · 2026Pooled it
- Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL.Blood advances · 2026Article
- Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.Paediatric drugs · 2026Review
- Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.Leukemia · 2026Article
- The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia.Molecular therapy. Oncology · 2026Review
- CD22 as a Target for Hematological Malignancies and Autoimmune Diseases.International journal of molecular sciences · 2026Review
- Prime Editing, CRISPR-Cas9, and NanoCas Genome Editing for Cancer Treatment.Molecular biotechnology · 2026Review
- CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.Blood advances · 2026Article
- CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy.NPJ precision oncology · 2026Article
- The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nature reviews. Clinical oncology · 2026Review
- Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026Review
- Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.Blood advances · 2026Article
- Advances in Chemotherapy in Pediatrics Acute Lymphocytic Leukemia (Pall): Actions, Associated Risks and Emerging Therapies.Current pharmaceutical design · 2026Review
- Bispecific antibody-drug conjugates: a modular blueprint for next-generation cancer therapeutics.Archives of pharmacal research · 2026Review
- Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL.Hematology. American Society of Hematology. Education Program · 2025Review
- The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era.Hematology. American Society of Hematology. Education Program · 2025Review
- Relapsed acute lymphoblastic leukemia: back to the drawing board.Haematologica · 2025Article
- Risk Stratification for Cardiotoxicity in Childhood Cancer Survivors: State-of-the-Art Review and a Novel Two-Step Approach.Cancers · 2025Review
- Tubulin inhibitors: an insight into new strategies to combat leukemia.Future medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 9 countries.
Edoardo Pennesi *Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Naomi Michels *Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Erica BrivioPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Vincent H J van der VeldenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0001-9457-3763
Yilin JiangPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Adriana ThanoPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Anneke J C AmmerlaanPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Judith M BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0003-4848-7789
H Berna BeverlooDepartment of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Barbara SleightPfizer Inc, Groton, CT, USA.
Ying ChenPfizer Inc, Groton, CT, USA.
Britta Vormoor-BürgerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Susana RivesPediatric Oncology and Hematology Department, Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5658-1831
Bella BieloraiDivision of Pediatric Hematology and Oncology, Sheba Medical Center, Ramat-Gan, Israel.
Claudia RössigPediatric Hematology and Oncology, University Children's Hospital Muenster, Münster, Germany.
Arnaud PetitDepartment of pediatric Hematology and Oncology, Hopital Armand Trousseau, APHP, Sorbonne Université, Paris, France.ORCID http://orcid.org/0000-0001-8363-1622
Carmelo RizzariPediatric Hematology-Oncology Unit, Department of Pediatrics, MBBM Foundation, ASST Monza, University of Milano-Bicocca, Monza, Italy.
Gernot EngstlerSt Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Jan StarýDepartment of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic.
Francisco J Bautista SirventPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Christiane Chen-SantelDepartment of Pediatrics, Division of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Benedicte BrunoPediatric Hematology, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France.
Yves BertrandInstitute of Pediatric Hematology and Oncology, Civil Hospital of Lyon, Claude Bernard University, Lyon, France.
Fanny RiallandService Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France.
Geneviève PlatService d'Hématologie-Immunologie-Oncologie, Hôpital des Enfants, CHU Toulouse, Toulouse, France.
Dirk ReinhardtDepartment of Pediatric Oncology, Essen University Hospital, Essen, Germany.
Luciana VintiDepartment of Hematology, Oncology and of Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesú, Sapienza, University of Rome, Rome, Italy.
Arend Von StackelbergDepartment of Pediatrics, Division of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Franco LocatelliDepartment of Hematology, Oncology and of Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesú, Sapienza, University of Rome, Rome, Italy.
Christian M ZwaanPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. c.m.zwaan@prinsesmaximacentrum.nl.ORCID http://orcid.org/0000-0001-6892-8268
Princess Máxima Center · NLBambino Gesù Children's Hospital · ITErasmus MC · NLOncode Institute · NLPfizer (United States) · USCentre Hospitalier Universitaire de Lille · FRCharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEHôpital des Enfants · FRHôpital Mère-Enfant · FRHospital Infantil Universitario Niño Jesús · ESHospital Sant Joan de Déu Barcelona · ESSheba Medical Center · ILSorbonne Université · FRSt Anna Children's Hospital · ATUniversité Claude Bernard Lyon 1 · FRUniversity Hospital in Motol · CZUniversity Hospital Münster · DEUniversity of Milano-Bicocca · ITUniversity of Rostock · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1-18 years, with R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m
Indexed as
CalicheamicinsPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseAdolescentChildChild, PreschoolHumansInfantInotuzumab OzogamicinProgression-Free SurvivalCalicheamicinsInotuzumab Ozogamicin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07476729ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.